KRAS and pancreatic neoplasm: MiR-96 is considered a potential tumor suppressor (directly targets and down-regulates the KRAS oncogene): in PDAC, it is significantly down-regulated when compared with normal pancreatic tissues; in human clinical specimens, an inverse correlation was observed between miR-96 and KRAS expression (miR-96 may have potential therapeutic use in KRAS-driven pancreatic cancer) [156].